147. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS): a Worldwide Antimicrobial Web-based Point Prevalence Survey
Session: Poster Abstract Session: Antimicrobial Stewardship: Current State and Future Opportunities
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • IDWeek-poster 147_Global-PPS_Herman-Goossens_27sept15.pdf (834.3 kB)
  • Background: Point Prevalence Surveys (PPS) are well established surveillance methods for monitoring antimicrobial prescribing in hospitals. The Global-PPS aimed to expand this method to monitor antimicrobial prescribing and resistance rates worldwide. bioMérieux provided unrestricted funding support for the survey.

    Methods: This survey invited hospitals worldwide admitting adults, children and neonates, to volunteer to participate. Data collected included age, gender, weight, antimicrobial agents, doses, reasons and indications for treatment, microbiological data, compliance to guidelines, documentation of reasons and stop/review date of prescription. Denominators included the total number of inpatients. A web-based application is used for data-entry, validation and reporting. Time frame of data collection is from February until September 2015.

    Results: So far, of 300 hospitals registered in the Global-PPS program, 223 hospitals (H) in 44 countries (C) entered data including Africa (3C, 6H), Asia (13C, 38H), Europe (21C, 147H), North-America (2C, 15H), South-America (3C, 14H) and Oceania (2C, 3H). Considering validated data only (N=21C, 69 H), overall antimicrobial prevalence was 31.1% (from 21.4% in Ireland to 66.8% in Nigeria). Cephalosporins (J01D) were most often prescribed in Russia (65.8%) and Serbia (52.9%). Highest penicillin prescribing (J01C) was in Ireland (50.0%) and the UK (47.5%); and highest quinolone use in Latvia (21.0%). Documentation of reason for treatment ranged from 17.7% (Nigeria) to 98.0% (Ireland) and of a stop/review date from 2.6% (Brazil) to 80.0% (Ireland). Guideline compliance ranged from 48.3% (Bosnia and Herzegovina) to 98.8% (Italy).

    Conclusion: This ongoing Global-PPS demonstrated that worldwide surveillance can be accomplished with voluntary participation. This Global-PPS provides quantifiable outcome measures that will be fed back to each centre comparing antimicrobial prescribing rates between participating centres, nations and continents. The Global-PPS allows for targeted quality improvements, the development of local prescribing guidelines, education and practice changes, and for measuring the impact of these interventions through repeated PPS.

    Ann Versporten, MEHS, MPH1, Nico Drapier, BAI1, Peter Zarb, Pharm[Hon], M.Phil, PhD2, Isabelle Caniaux, PharmD3, Marie-Françoise Gros, MD3, Mark Miller, MD3, Vincent Jarlier, MD, PhD4, Dilip Nathwani, MD, PhD5 and Herman Goossens, MD, PhD1, (1)Laboratory of Medical Microbiology, University of Antwerp, Antwerp, Belgium, (2)Mater Dei Hospital, Msida, Malta, (3)bioMérieux, Marcy l'Etoile, France, (4)Laboratoire De Bactériologie-Hygiène, Faculté de Médecine Pitié-Salpêtrière, Paris, France, (5)Ninewells Hospital and Medical School Dundee, Dundee, Scotland

    Disclosures:

    A. Versporten, None

    N. Drapier, None

    P. Zarb, None

    I. Caniaux, bioMerieux: Employee , Salary

    M. F. Gros, bioMérieux: Employee , Salary

    M. Miller, bioMerieux: Employee , Salary

    V. Jarlier, None

    D. Nathwani, None

    H. Goossens, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.